T he number of HIV infections acquired in west Africa and diagnosed in England, Wales, and Northern Ireland (E,W&NI) has risen in recent years. 1 In west Africa, adult HIV prevalence ranges from less than 1% in Mauritania to 7% in Ivory Coast. 2 In this region, the epidemic is diverse and changeable with overall figures often concealing very high infection levels among certain population groups. 2 An estimated 35 000 people migrated from west Africa to the United Kingdom between 1998 and 2002, 3 and an increasing number of UK nationals travel to the region each year. An estimated 130 000 visits were made in 2002, nearly half to visit friends and family. 4 To date, the majority of HIV-2 infections diagnosed in E,W&NI have been acquired in west Africa. 5 HIV-2 infection is endemic in west Africa, with further spread to countries with strong links to the region. While HIV-2 is less pathogenic than HIV-1, with prolonged periods of asymptomatic infection, 6 the diagnosis of HIV-2 infection has implications for choice of antiretroviral therapy 7 8 ; the clinical management of pregnant women to prevent mother to child transmission 9 10 ; the diagnosis and monitoring of HIV infection in children born to HIV infected pregnant women; and the quantification of HIV-2 RNA, as no commercial assays are currently available. 9 We describe diagnoses, including those of HIV-2 infection, made in E,W&NI among those probably infected in west Africa, and consider whether there is evidence for ongoing heterosexual transmission within the United Kingdom.
METHODS
The Communicable Disease Surveillance Centre (CDSC) receives voluntary and confidential reports of HIV diagnoses in adults (15+ years) in E,W&NI from laboratories (since 1985) and clinicians (since 2000).
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Probable route of infection (for example, sex between men, injecting drug use) is collected for all reports and followed up where missing. Probable country of infection is collected for all reports but is only followed up for those infected through heterosexual intercourse. The question takes the format: ''Patient presumed infected in the United Kingdom? [Y/N/ NK]. If no, in which country(ies)?'' If an individual is presumed infected through sex between men and women within the United Kingdom, then the partner's probable route and country of infection are also recorded. Where more than one possible country of infection is given, the country with highest HIV prevalence is allocated. Here, west Africa is taken to include Benin, Burkina Faso, Cape Verde, Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, St Helena, and Togo, as defined by the United Nations.
HIV type (HIV-1, HIV-2, or HIV-1/HIV-2 co-infection) is collected for all reports of HIV diagnoses made to CDSC, and followed up if reported as HIV-2 or HIV-1/HIV-2 co-infection for verification. In UK laboratories, HIV-1 infection is assumed if one of three reactive screening assays incorporating only HIV-1 antigen is used and reactivity is not unexpectedly low. In the case of a weak or negative reaction in the HIV-1 specific assay, either HIV-2 infection or recent HIV-1 seroconversion are considered. 12 A ''line assay,'' such as Liatek/Innolia, or a rapid test device, which incorporates type specific reaction spots, are often employed to discriminate between HIV-1 and HIV-2 infection.
12 Suspected anti-HIV-2 positive, dually reactive specimens, and other specimens with anomalous results are referred to a reference laboratory where they are tested by a variety of additional discriminatory methods that may include a native antigen based western blot. 12 Median ages and interquartile ranges (IQR) were calculated using Epi-Info 6 (v. 
Probably infected in west Africa
Of the 1324 adults diagnosed in E,W&NI who were probably infected in west Africa, 917 (69%) were HIV-1-infected and 52 (6%) were HIV-2 or HIV-1/HIV-2 co-infected. For 355 (27%) the HIV type was not reported. The number of HIV-2 infections and HIV-1/HIV-2 co-infections diagnosed over time remained relatively constant ( fig 1A) .
Of the total probably infected in west Africa (1324), 728 (55%) were women and 596 were men, with median ages at diagnosis of 30 years (IQR 26-35 years) and 36 years (IQR 30-43 years), respectively. In all, 223 women (31%) were pregnant at diagnosis (six were HIV-2 positive). Where reported (1147), 1057 (92%) were black African, 64 (6%) were white, and the remainder other ethnicities. Country of birth was reported for 613 (46%) individuals: 428 (70%) were born in west Africa, 144 (23%) in other African regions, 34 in the United Kingdom, and the remainder elsewhere. Of the total (1324), 1050 (79%) were diagnosed in London.
Of the 1324 infections, 1269 (96%) were probably infected through heterosexual intercourse, 29 through sex between men, 16 through blood transfusion, and 10 through other routes. Over 40% of the 1324 infections were acquired in Nigeria, 24% in Ghana, 17% in Ivory Coast, 8% in Sierra Leone, 5% in the Gambia, and the remainder in other west African countries (table 1) . The ratio of HIV-2 and HIV-1/ HIV-2 co-infections to HIV-1 varied by country of infection, with the Gambia (11.7%-15.2%) and Ivory Coast (7.2%-9.8%) having a high proportion of HIV-2 infections, and Nigeria (0.7%-1.0%) a low proportion.
Women infected with HIV-2 were older at diagnosis than those infected with HIV-1 (35 years (IQR 32-36 years) versus 30 years (IQR 26-34 years)). With the exception of country of infection, there were no other differences in the demographics and characteristics of those infected with HIV-1 and HIV-2 (data not shown).
Probably infected through heterosexual intercourse within the United Kingdom by a heterosexual partner infected in west Africa Of the 130 adults infected through heterosexual intercourse within the United Kingdom by a heterosexual partner infected in west Africa, 89 (68%) were HIV-1 infected and three (2%) were HIV-2 or HIV-1/HIV-2 infected. For 38 (29%), HIV type was not reported (fig 1B) .
Of the total (130), 114 (88%) were women and 16 men, with median ages at diagnosis of 31 years (IQR 25-35 years) and 40 years (IQR 38-50 years), respectively. Twenty three women (20%) were pregnant at diagnosis. Where reported (113), 55 (49%) patients were black African, 46 (41%) white, and the remainder of other ethnicities. Country of birth was reported for 69 (53%) individuals: 32 (46%) were born in the United Kingdom , 28 (41%) in Africa and the remainder in other regions. Where the partner's probable west African country of infection was reported (126), 57 (45%) partners were probably infected in Nigeria, 44 (35%) in Ghana, and the remainder in other countries. Ninety two (71%) individuals were diagnosed in London. Just over half of those infected in west Africa and diagnosed in E,W&NI were women, of whom nearly a third were pregnant at diagnosis. The majority were infected through heterosexual intercourse; were black African; and were born in Africa, mainly west Africa. By contrast, of those infected heterosexually in the United Kingdom by a heterosexual partner infected in west Africa, over 90% were women, of whom a fifth were pregnant at diagnosis. Half were black African and 40% African born.
Broadly, the proportion of HIV diagnoses in E,W&NI associated with different west African countries reflects their population size, HIV prevalence, and the size of the respective population resident in the United Kingdom. Over 40% of those infected in west Africa were probably infected in Nigeria, which has a population of over 135 million and HIV prevalence of 5.4%. 2 13 In 2001, there were over 86 000 people born in Nigeria residing in E&W, representing over 40% of all residents born in west and central Africa. 14 The proportion of HIV-2 diagnoses also differed by west African countries of infection. Upper estimates indicate that 15% of those infected in the Gambia and diagnosed in E,W&NI were HIV-2 positive, as were 10% of people infected in Ivory Coast and 7% of those infected in Ghana. While 40% of those infected in west Africa were probably infected in Nigeria, only 1% of these individuals were HIV-2 positive. HIV-2 infected women were older than HIV-1 infected women, which may reflect the longer asymptomatic period of HIV-2 infection; older age at infection, or at least diagnosis, with HIV-2; or possible differences in patterns of migration between HIV-1 and HIV-2 infected women.
Miscategorisation of probable country of infection may have occurred by allocating the country of highest prevalence as the likely country of infection. The number of infections acquired within the United Kingdom from a partner infected in west Africa may therefore be underestimated, particularly among those resident in the United Kingdom but originating from west Africa. In addition, the number of men who have sex with men infected in west Africa may be underestimated, as country of infection is followed up only for heterosexuals when missing. Data on country of birth were only available for those reported on clinician HIV reports since 2000 (,50%) and although probably known, HIV type was not reported for over a quarter of individuals. It is unclear whether data incompleteness caused any biases in results. Previous research suggests that HIV-2 diagnoses are not underreported within E,W&NI (CDSC, unpublished), and the assumption that those without HIV type reported are likely to be HIV-1 infected guides the lower estimate of the proportions given in the results table.
Within the context of the overall HIV epidemic in E,W&NI, numbers of HIV diagnoses associated with west Africa are modest compared to those of infections associated with eastern Africa and more recently with south eastern Africa. 1 15 There have been 4809 infections probably acquired in east Africa diagnosed in E,W&NI between 1985 and 2003 and a further 188 individuals diagnosed who were probably infected through heterosexual intercourse within the United Kingdom by a partner who was heterosexually infected in east Africa (CDSC, unpublished). Equivalent figures for south east Africa are 5779 and 217, respectively (CDSC, unpublished). In terms of HIV-2, the United Kingdom has experienced a lower prevalence of HIV-2 infection compared to some other European countries, for example Portugal and France. 16 Prevalence of HIV-2 infection among STI clinic attendees in the United Kingdom was 0.006% (6/104 006) in 2002, as measured by the Unlinked Anonymous Prevalence Monitoring Programme. 17 In conclusion, the number of people infected with HIV in west Africa and diagnosed in E,W&NI has increased in recent years, and there has also been an increase in HIV infections acquired through heterosexual intercourse within the United Kingdom from a partner infected in west Africa. Health promotion specialists and west African communities in E,W&NI need to be alerted to these increases so that appropriate measures can be taken to prevent further transmission. While the number of HIV-2 diagnoses remain relatively low and constant over time clinicians should be aware that for some west African countries the proportion of HIV-2 diagnoses is high, which has implications for HIV diagnostics and treatment: there are currently no commercial assays available for HIV-2 RNA quantification and conflicting evidence about whether HIV-2 viral loads are useful in clinical management [7] [8] [9] ; those infected with HIV-2 are naturally resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs); HIV-2 infected pregnant women may not need to be given antiretroviral therapy and a caesarean section 9 10 ; and there are difficulties in diagnosing and monitoring HIV infection among children born to HIV-2 infected mothers.
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